Zwerling AA - Search Results

1

Cost-effectiveness of 3-months isoniazid and rifapentine compared to 9-months isoniazid for latent tuberculosis infection: a systematic review.

Lai WA, Brethour K, D'Silva O, Chaisson RE, Zwerling AA. Lai WA, et al. Among authors: zwerling aa. BMC Public Health. 2022 Dec 7;22(1):2292. doi: 10.1186/s12889-022-14766-6. BMC Public Health. 2022. PMID: 36476206 Free PMC article.

2

Tuberculosis and homelessness in Montreal: a retrospective cohort study.

Tan de Bibiana J, Rossi C, Rivest P, Zwerling A, Thibert L, McIntosh F, Behr MA, Menzies D, Schwartzman K. Tan de Bibiana J, et al. BMC Public Health. 2011 Oct 28;11:833. doi: 10.1186/1471-2458-11-833. BMC Public Health. 2011. PMID: 22034944 Free PMC article.

3

Screening for Tuberculosis Among Adults Newly Diagnosed With HIV in Sub-Saharan Africa: A Cost-Effectiveness Analysis.

Zwerling AA, Sahu M, Ngwira LG, Khundi M, Harawa T, Corbett EL, Chaisson RE, Dowdy DW. Zwerling AA, et al. J Acquir Immune Defic Syndr. 2015 Sep 1;70(1):83-90. doi: 10.1097/QAI.0000000000000712. J Acquir Immune Defic Syndr. 2015. PMID: 26049281 Free PMC article.

4

A simplified cost-effectiveness model to guide decision-making for shortened anti-tuberculosis treatment regimens.

Zwerling A, Gomez GB, Pennington J, Cobelens F, Vassall A, Dowdy DW. Zwerling A, et al. Int J Tuberc Lung Dis. 2016 Feb;20(2):257-60. doi: 10.5588/ijtld.15.0415. Int J Tuberc Lung Dis. 2016. PMID: 26792481

5

Cost and cost-effectiveness of tuberculosis treatment shortening: a model-based analysis.

Gomez GB, Dowdy DW, Bastos ML, Zwerling A, Sweeney S, Foster N, Trajman A, Islam MA, Kapiga S, Sinanovic E, Knight GM, White RG, Wells WA, Cobelens FG, Vassall A. Gomez GB, et al. BMC Infect Dis. 2016 Dec 1;16(1):726. doi: 10.1186/s12879-016-2064-3. BMC Infect Dis. 2016. PMID: 27905897 Free PMC article.

6

Revisiting annual screening for latent tuberculosis infection in healthcare workers: a cost-effectiveness analysis.

Mullie GA, Schwartzman K, Zwerling A, N'Diaye DS. Mullie GA, et al. BMC Med. 2017 May 17;15(1):104. doi: 10.1186/s12916-017-0865-x. BMC Med. 2017. PMID: 28514962 Free PMC article.

7

Incorporating social justice and stigma in cost-effectiveness analysis: drug-resistant tuberculosis treatment.

Zwerling A, Dowdy D, von Delft A, Taylor H, Merritt MW. Zwerling A, et al. Int J Tuberc Lung Dis. 2017 Nov 1;21(11):69-74. doi: 10.5588/ijtld.16.0839. Int J Tuberc Lung Dis. 2017. PMID: 29025487 Free PMC article.

8

Cost of three models of care for drug-resistant tuberculosis patients in Nigeria.

Bada FO, Okpokoro E, Blok N, Meribole E, Dutt S, Dakum P, Abimiku A, Zwerling A, Kik SV. Bada FO, et al. BMC Infect Dis. 2019 Jan 10;19(1):41. doi: 10.1186/s12879-018-3636-1. BMC Infect Dis. 2019. PMID: 30630429 Free PMC article.

9

The latent tuberculosis infection cascade of care in Iqaluit, Nunavut, 2012-2016.

Pease C, Zwerling A, Mallick R, Patterson M, Demaio P, Finn S, Allen J, Van Dyk D, Alvarez GG. Pease C, et al. BMC Infect Dis. 2019 Oct 24;19(1):890. doi: 10.1186/s12879-019-4557-3. BMC Infect Dis. 2019. PMID: 31651260 Free PMC article.

10

The implementation of rifapentine and isoniazid (3HP) in two remote Arctic communities with a predominantly Inuit population, the Taima TB 3HP study.

Alvarez GG, Van Dyk D, Mallick R, Lesperance S, Demaio P, Finn S, Potvin SE, Patterson M, Pease C, Amaratunga K, Hui C, Cameron DW, Mulpuru S, Aaron SD, Momoli F, Zwerling A. Alvarez GG, et al. Int J Circumpolar Health. 2020 Dec;79(1):1758501. doi: 10.1080/22423982.2020.1758501. Int J Circumpolar Health. 2020. PMID: 32379538 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

61 results

Search Page

Filters